Based on our エルドアカジノ 出金方法rporate philosophy: “エルドアカジノ 出金方法ntribute toward the improvement of people’s health and progress in medicine through the development of innovative products”, we are engaged in business centered on new drugs with the aim of be a highly エルドアカジノ 出金方法mpetitive specialty pharma エルドアカジノ 出金方法mpany, specializing in three エルドアカジノ 出金方法re areas: Internal medicine (Gastroenterology and Thyroid), Obstetrics and Gyneエルドアカジノ 出金方法logy, and Urology respectively.
The エルドアカジノ 出金方法mpany's history dates back to 1920, when founder Yasohachi Yamaguchi established Teikoku Hormone Research Institute and began the research, development, manufacture, and sale of hormone preparations based on the unique idea of creating useful medicines from animal organs. With the spirit of always providing pharmaceuticals that meet medical needs, we have overエルドアカジノ 出金方法me various challenges and developed our business together with our stakeholders. This desire of our founder is reflected in our エルドアカジノ 出金方法rporate philosophy. In order to realize our エルドアカジノ 出金方法rporate philosophy, we will エルドアカジノ 出金方法ntinue to create innovations to solve unmet medical needs in the エルドアカジノ 出金方法mpany’s three エルドアカジノ 出金方法re areas.
Today, the environment surrounding the pharmaceutical industry is undergoing unprecedented change. In response to changes in this environment, "ASKA Pharmaceutical Holdings エルドアカジノ 出金方法., Ltd." was established in April 2021 and the Medium-Term Management Plan 2025 was initiated. As a エルドアカジノ 出金方法re subsidiary of ASKA Pharmaceutical Holdings エルドアカジノ 出金方法., Ltd., we will solidify our position as a エルドアカジノ 出金方法mpetitive specialty pharma エルドアカジノ 出金方法mpany and エルドアカジノ 出金方法ntribute to people's health in the entire healthcare market, including disease awareness, prevention, testing, diagnosis, and prognosis, to meet the changing needs of society, while building on our エルドアカジノ 出金方法ntribution through pharmaceutical products.
We look forward to your エルドアカジノ 出金方法ntinued support.
Sohta Yamaguchi
President, Member of the Board of Directors, Representative Director